Yale’s Post ASH Review: Highlights from the 2023 American Society of Hematology Annual Meeting

For more information and to register:
https://yale.cloud-cme.com/course/courseoverview?P=5&EID=42193

Due to time constraints, many oncologists and researchers are unable to participate in all portions of the ASH Annual Meeting, which provides the latest hematology advances and research to the global hematology community. This one-day hybrid activity provides local hematologists, general internists, and researchers with up-to-date information presented at the ASH Annual Meeting from Yale Cancer Center faculty.

Objectives:

1. Describe the current treatment options and updates in various lymphoma, multiple myeloma, leukemia, and myeloid malignancies.
2. Discuss the development and outcomes of clinical research trials, cellular therapies, and transplant options for hematological malignancies and assess their relevance to patient care
3. Assess the emerging role of immunotherapy, targeted therapies, cellular therapies and antibodies in hematological malignancies
4. Review updates in classical hematology, including bleeding disorders and thrombosis